title: High-risk prostate cancer: the role of surgical management.
abstract: High-risk prostate cancer (HR Pca) is a highly heterogeneous disease from a biological and clinical standpoint, and it carries a significant chance of morbidity and mortality. Despite the impact of PSA screening, a significant number of men continue to present with high risk disease and need adequate management: clinical evidence shows that a considerable fraction on men with HR PCa can be actually cured with either uni- or multi-modality approaches. Surgical treatment, once considered unfeasible in this setting, is acquiring more and more diffusion in modern clinical practice. Herein we discuss the main treatment strategies for high-risk prostate cancer, providing an expert opinion on the role of surgical management and its outcomes in the most recent literature.
authors.affiliation: Urology Department, Mayo Clinic, Rochester, MN, USA; Department of Surgical, Oncological and Gastroenterological Sciences, Urology Clinic, University of Padova, Padova, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Morlacco
authors.affiliation: Urology Department, Mayo Clinic, Rochester, MN, USA. Electronic address: Karnes.R@mayo.edu.
authors.forename: R Jeffrey
authors.initials: RJ
authors.lastname: Karnes
mesh_terms: D006801:Humans; D008197:Lymph Node Excision / Q000009:adverse effects; D008297:Male; D020360:Neoadjuvant Therapy; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000601:surgery*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen
keywords: High risk; Prostate cancer; Prostate surgery; Radiation therapy; Radical prostatectomy